Identification of hepatitis B virus rtS117f substitution as a compensatory mutation for rtM204I during lamivudine therapy

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 39-48

  Lin, Chih Lang ^a   Chien, Rong Nan ^a   Hu, Ching Chih ^a   Lai, Ming Wei ^a   Yeh, Chau Ting ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Lamivudine resistance; Replication deficiency; Site directed mutagenesis; Virion secretion

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; VIRAL GENETICS; VIRION; VIROTHERAPY; VIRUS IDENTIFICATION; VIRUS MUTATION; VIRUS REPLICATION; AGED; AMINO ACID SUBSTITUTION; DNA SEQUENCE; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

EID: 84859207020     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr416     Document Type: Article

References (21)

1. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-33.
2. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003; 51: 761-85.
3. Yeh CT, Chien RN, Chu CM et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318-26.
4. Torresi J, Earnest-Silveira L, Civitico G et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299: 88-99.
5. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
6. Osborn MK, Lok AS. Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006; 57: 1030-4.
7. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78 Suppl 1: S52-5.
8. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.e2.
9. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 Suppl: S174-84.
10. Warner N, Locarnini S, Kuiper M et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudineresistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51: 2285-92.
11. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-6.
12. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005; 34 Suppl 1: S143-6.
13. Sheldon J, Rodès B, Zoulim F et al. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006; 13: 427-34.
14. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132: 1574-85.
15. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
16. Enomoto M, Tamori A, Kohmoto MT et al. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J Med Virol 2007; 79:1664-70.
17. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-55.
18. Delaney WE IV, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-41.
19. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010; 15: 471-5.
20. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profileof viral rebound. Hepatology 2008; 48:88-98.
21. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008; 13: 875-9.